* AngioDynamics Inc is expected to show a fall in quarterly revenue when it reports results on January 8 for the period ending November 30 2024
* The Latham New York-based company is expected to report a 10.3% decrease in revenue to $70.933 million from $79.07 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
* LSEG's mean analyst estimate for AngioDynamics Inc is for a loss of 11 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for AngioDynamics Inc is $13.00, above its last closing price of $9.08.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Aug. 31 2024 -0.15 -0.15 -0.11 Beat 25
May. 31 2024 -0.16 -0.17 -0.06 Beat 64
Feb. 29 2024 -0.13 -0.14 -0.16 Missed -18.3
Nov. 30 2023 -0.09 -0.07 -0.05 Beat 33.3
Aug. -0.13 -0.13 -0.12 Beat 7.7
31 2023
May. 31 2023 0.03 0.02 0.02 Met -11.1
Feb. 28 2023 -0.01 -0.01 -0.03 Missed -300
Nov. 30 2022 -0.01 -0.01 0.01 Beat 200
This summary was machine generated January 6 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。